A Single-blind, Intra-individual, Crossover, Multicenter Study of the Efficacy, Safety and Tolerability of Gadavist (1.0 M) in Comparison With Magnevist (0.5 M) as Contrast Agent in the Enhanced Magnetic Resonance Angiography (MRA) in Chinese Patients
Latest Information Update: 06 Nov 2021
At a glance
- Drugs Gadobutrol (Primary) ; Gadopentetic acid
- Indications Vascular disorders
- Focus Diagnostic use
- Sponsors Bayer
Most Recent Events
- 11 May 2014 New trial record